Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2002-01-03
2008-11-04
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S007400
Reexamination Certificate
active
07446097
ABSTRACT:
The present invention relates to novel compounds represented by the structure I and pharmaceutical preparations thereof for the treatment of inflammatory diseases in humans and animals.
REFERENCES:
patent: 4710495 (1987-12-01), Bodor
patent: 6566509 (2003-05-01), Griffin et al.
patent: 0283055 (1990-08-01), None
patent: 0771564 (1997-05-01), None
patent: 0774589 (1997-05-01), None
patent: 2776927 (1999-10-01), None
patent: 1-163124 (1989-06-01), None
patent: 9213872 (1992-08-01), None
patent: 9213873 (1992-08-01), None
patent: 9413690 (1994-06-01), None
patent: 9414834 (1994-07-01), None
patent: WO-97/41255 (1997-11-01), None
patent: 9964040 (1999-12-01), None
patent: 0042055 (2000-07-01), None
patent: 03/070174 (2003-08-01), None
Anderson, R. et al., “An in-vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent,” Journal of Antimicrobial Chemotherapy, 1988 22, pp. 923-933.
Fietta, A. et al., “Requirements for Intracellular Accumulation and Release of Clarithromycin and Azithromycin by Human Phagocytes,” Journal of Chemotherapy, 1997, vol. 9—n.1, pp. 23-31.
Schentag, J.J. et al., “Relationships Between Serum, Intracellular, and Infection Site Concentrations of Macrolide and Azalide Antibiotics: A Theoretical Exploration of the Concept of White Blood Cell Drug Delivery to Infection Sites,” Antiinfective Drugs and Chemotherapy, 1996, vol. 14, No. 2, pp. 137-146.
Vazifeh, D. et al., “Cellular Accumulation of the New Ketolide RU 64004 by Human Neutrophils: Comparison with That of Azithromycin and Roxithromycin,” Antimicrobial Agents and Chemotherapy, Oct. 1997, vol. 41, No. 10, pp. 2099-2107.
Romo, D. et al., “Total Synthesis and Immunosuppressive Activity of (−)-Pateamine A and Related Compounds: Implementation of a β-Lactam-Based Macrocyclization,” Journal of American Chemical Society, 1998, 120, pp. 12237-12254.
Griffith, E. et al., “[7] Yeast Three-Hybrid System for Detecting Ligand-Receptor Interactions,” Methods in Enzymology, 2000, vol. 328, pp. 89-103.
Abdelghaffar et al.; “Erythromycin A-Derived Macrolides Modify the Functional Activites of Human Neutrophils by Altering the Phospholipase D-Phosphatidate Phosphohydrolase Transduction Pathway: L-Cladinose Is Involved Both in ALterations of Neutrophil Functions and Modulation of This Transductional Pathway”; Journal of Immunology; 1997; vol. 159, No. 8; pp. 3995-4005.
Agouridas et al.; “Synthesis and Antibacterial Activity of Ketolides (6-O-Methyl-3-Oxoerythromycin Derivatives): A New Class Antibacterials Highly Potent Against Macrolide-Resistant and Susceptible Respiratory Pathogens”; Journal of Medicinal Chemistry; 1998; vol. 41, No. 21; pp. 4080-4100.
Geerdes-Fenge H F et al.; “Comparative Pharmacokinetics of Dirithromycin and Erythromycin in Normal Volunteers with Special Regard to Accumulation in Polymorphonuclear Leukocytes and in Saliva”; European Journal of Clinical Pharmacology; 1997; vol. 53, No. 2; pp. 127-133.
Glaude et al.; “In Vitro and In Vivo Uptake of Azithromycin (CP-62,993) by Phagocytic Cells: Possible Mechanism of Delivery and Release at Sites of Infection”; Antimicrobial Agents and Chemotherapy; 1989; Vol. 33, No. 3; pp. 277-282.
Ianaro et al.; “Anti-Inflammatory Activity of Macrolide Antibiotics”; Journal of Pharmacology and Experimental Therapeutics; 2000; vol. 292, No. 1; pp. 156-163.
Kertesz et al.; “Thiol Esters from Steroid 17β-Carboxylic Acids: Carboxylate Activation and Internal Participation by 17α-Acylates”; Journal of Organic Chemistry; 1986; vol. 51; pp. 2315-2328.
Khosla et al.; “Streptogramins: a New Class of Antibiotics”; Indian Journal of Medical Sciences; 1999; vol. 53, No. 3; pp. 111-119.
Labro; “Anti-Inflammatory Activity of Macrolides: A New Therapeutic Potential?”; Journal of Antmicrobial Chemotherapy; 1998; vol. 41, Suppl. B; pp. 37-46.
Little et al.; “Soft Drugs Based on Hydrodortisone: the Inactive Metabolite Approach and Its Application to Steroidal Antiinflammatory Agents”; Pharmaceutical Research; 1999; vol. 16, No. 6; pp. 961-967.
McLean et al.; “Novel Fluorinated Antiinflammatory Steroid with Reduced Side Effects: Methyl 9α-Fluoroprednisolone-16-Carboxylate”; Journal of Pharmaceutical Sciences; 1994; vol. 83, No. 4; pp. 476-480.
Mikasa et al.; “The Anti-Inflammatory Effect of Erythromycin in Zymosan-Induced Peritonitis of Mice”; Journal of Antmicrobial Chemotherapy; 1992; vol. 30; pp. 339-348.
Olsen et al.; “Intrapulmonary Pharmacokinetics of Azithromycin in Healthy Volunteers Given Five Oral Doses”; Antimicrobial Agents and Chemotherapy; 1996; vol. 40, No. 11; pp. 2582-2585.
Scorneaux et al.; “Intracellular Accumlation, Subcellular Distribution, and Efflux of Tilmicosin in Bovine Mammary, Blood, and Lung Cells.”; Journal of Diary Science; 1999; vol. 82, No. 6; pp. 1202-1212.
Suzuki et al.; “General and Facile Method for Determination of Configuration of Steriod-17-yl Methyl Glycolates at C-20 Based on Kinetic Examination”; Journal of the Chemical Society, Perkin Transactions I; 1998; pp. 3831-3836.
Takizawa et al.; “Erythromycin Modulates IL-8 Expression in Normal and Inflamed Human Bronchial Epithelial Cells”; American Journal of Respiratory and Critical Care Medicine; 1997; vol. 156, No. 1; pp. 266-271.
Travers; “Novel Immunomodulators for Topical Skin Diease Therapy”; Expert Opinion on Investigational Drugs; 2000; vol. 9, No. 3; pp. 529-542
U.S. Appl. No. 10/830,858 filed Apr. 22, 2004.
U.S. Appl. No. 11/201,685 filed Aug. 10, 2005.
U.S. Appl. No. 11/355,808 filed Feb. 15, 2006.
U.S. Appl. No. 11/718,505 filed May 2, 2007.
U.S. Appl. No. 11/813,882 filed Jul. 13, 2007.
U.S. Appl. No. 11/813,884 filed Jul. 13, 2007.
Hrvacic Boska
Komac Marijana
Markovic Stribor
Mercep Mladen
Mesic Milan
Glaxosmithkline Istrazivacki Centar Zagreb D.O.O
Peselev Elli
Strickland J. Michael
LandOfFree
Conjugates of immune cell specific macrolide compounds with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conjugates of immune cell specific macrolide compounds with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conjugates of immune cell specific macrolide compounds with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4026176